Chinese Regulator Approves DAXXIFY for Registration

MT Newswires Live

Sep 09, 2024

The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.

Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.

The original licensor, the US-based Revance Therapeutics, is the right holder of the product in the region.

The company's shares were down 7% on Monday's close.

Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466166009"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466166009\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466166009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-09 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466166009","market":"fut","top_or_hot":-1,"title":"Chinese Regulator Approves DAXXIFY for Registration","media":"MT Newswires Live","content":"<html><body><p>Chinese Regulator Approves DAXXIFY for Registration</p><p> The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.</p><p>Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.</p><p>The original licensor, the US-based Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is the right holder of the product in the region.</p><p>The company's shares were down 7% on Monday's close.</p><p>Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%</p></body></html>","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Regulator Approves DAXXIFY for Registration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Regulator Approves DAXXIFY for Registration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-09 19:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese Regulator Approves DAXXIFY for Registration The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466166009","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466166009","pubTimestamp":1725882471,"columns":[],"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Chinese Regulator Approves DAXXIFY for Registration The National Medical Products Administration has","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","NHLD":"National Holdings Corporation","BK1100":"医疗保健设备","BK4526":"热门中概股","01696":"复锐医疗科技","BK4588":"碎股","00656":"复星国际","BK1593":"医美概念股","BK4585":"ETF&股票定投概念","BK4023":"应用软件","HKD":"尚乘数科","BK1585":"昨日强势股","RVNC":"Revance Therapeutics Inc","BK1230":"工业集团企业"},"translate_title":"中国监管机构批准DAXXIFY注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01696":1,"NHLD":1,"00656":1,"RVNC":1,"HKD":1},"content_text":"Chinese Regulator Approves DAXXIFY for Registration The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.The original licensor, the US-based Revance Therapeutics, is the right holder of the product in the region.The company's shares were down 7% on Monday's close.Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}